AI Medical Service (AIM) has obtained regulatory approval from Thailand’s Food and Drug Administration (FDA) for its AI-based endoscopic diagnosis support system, gastroAI-model G.
The software helps in distinguishing between neoplastic and non-neoplastic gastric lesions using artificial intelligence.
It is the first approval in Thailand for an AI-powered diagnostic support system targeting the upper gastrointestinal tract.
Gastric cancer is the fifth most common cancer globally, affecting over one million people annually and resulting in around 600,000 deaths each year.
AIM aims to address the anticipated shortage of endoscopy specialists by introducing its gastric cancer diagnostic support AI to Thailand.
The gastroAI-model G analyses endoscopic images to determine the nature of gastric lesions.
It provides immediate feedback to physicians, indicating whether a lesion is likely neoplastic, non-neoplastic, or of low confidence.
The system also displays the visual similarity of the lesion to historical neoplastic cases and highlights the lesion’s location on the image.
AI Medical Service, also known as AIM, is a medical start-up that develops AI technology by harnessing the expertise of Japanese endoscopists.
Apart from the gastroAI-model G, the company also develops the Endoscopic AI solution, which can classify gastric cancer, and plans to launch it in the next spring.
Endoscopic AI has been trained with over 150,000 endoscopic videos from around 100 medical institutions.
